|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 408.70 DKK | +1.31% |
|
+2.33% | -12.37% |
| 02-09 | DNB Carnegie Lowers Price Target for Zealand Pharma to 595 Danish Kroner (610), Reiterates Buy | FW |
| 02-04 | U.S. Futures, European Stocks Rise | DJ |
Company Valuation: Zealand Pharma A/S
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 8,766 | 6,271 | 10,366 | 21,785 | 50,548 | 28,788 | 28,788 | - |
| Change | - | -28.46% | 65.31% | 110.16% | 132.03% | -43.05% | 0% | - |
| Enterprise Value (EV) 1 | 7,638 | 5,364 | 9,712 | 20,152 | 42,714 | 17,187 | 17,193 | 18,159 |
| Change | - | -29.78% | 81.08% | 107.49% | 111.96% | -59.76% | 0.04% | 5.62% |
| P/E ratio | -10x | -6.11x | -7.74x | -30x | -44.1x | 4.84x | 39.6x | -92.8x |
| PBR | 6.89x | 6.83x | 11.4x | 13.7x | 5.87x | 1.97x | 1.86x | 1.94x |
| PEG | - | -0.8x | -0.81x | 0.6x | -1.4x | -0x | -0.5x | 1x |
| Capitalization / Revenue | 24.8x | 21.4x | 99.7x | 63.6x | 806x | 3.26x | 6.65x | 8.52x |
| EV / Revenue | 21.6x | 18.3x | 93.4x | 58.8x | 681x | 1.95x | 3.97x | 5.38x |
| EV / EBITDA | -10.2x | -5.3x | -13.5x | -36.8x | -34.3x | 2.68x | 25.5x | -13.8x |
| EV / EBIT | -9.64x | -5.1x | -11.6x | -35.2x | -33.6x | 2.64x | 19.9x | -16.7x |
| EV / FCF | -10.7x | -4.35x | -10.2x | -46.1x | -45.4x | 2.8x | 12x | -20.4x |
| FCF Yield | -9.34% | -23% | -9.82% | -2.17% | -2.2% | 35.7% | 8.35% | -4.91% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -22.07 | -23.75 | -26.02 | -12.44 | -16.24 | 83.43 | 10.19 | -4.349 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 353.3 | 292.6 | 104 | 342.8 | 62.69 | 8,829 | 4,326 | 3,378 |
| EBITDA 1 | -749.7 | -1,012 | -719.2 | -547.2 | -1,246 | 6,416 | 673.7 | -1,312 |
| EBIT 1 | -792.4 | -1,052 | -837.2 | -572.2 | -1,272 | 6,508 | 864.3 | -1,087 |
| Net income 1 | -846.7 | -1,018 | -1,202 | -703.7 | -1,079 | 5,887 | 803.3 | -618.4 |
| Net Debt 1 | -1,127 | -906.9 | -653.8 | -1,633 | -7,834 | -11,601 | -11,595 | -10,629 |
| Reference price 2 | 220.60 | 145.10 | 201.40 | 373.20 | 715.50 | 403.40 | 403.40 | 403.40 |
| Nbr of stocks (in thousands) | 39,735 | 43,216 | 51,470 | 58,374 | 70,647 | 70,437 | 70,437 | - |
| Announcement Date | 3/11/21 | 3/10/22 | 3/1/23 | 2/27/24 | 2/20/25 | - | - | - |
1DKK in Million2DKK
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 4.84x | 1.9x | 2.62x | -.--% | 4.51B | |
| 47.29x | 11.15x | 40.2x | 0.02% | 50.89B | |
| 17.62x | 6.39x | 14.06x | 1.69% | 44.34B | |
| -25.47x | 51.26x | -29.11x | -.--% | 31.66B | |
| -26.94x | 4.61x | -12.72x | -.--% | 27.45B | |
| 30.57x | 6.64x | 18.4x | -.--% | 21.91B | |
| 15.96x | 3.7x | 9.79x | -.--% | 18.41B | |
| -181.52x | 44.77x | -181.02x | -.--% | 13.07B | |
| -317.95x | 25x | 1052.16x | -.--% | 12.4B | |
| -11.54x | 144.19x | -22.48x | -.--% | 11.76B | |
| Average | -44.71x | 29.96x | 89.19x | 0.17% | 23.64B | |
| Weighted average by Cap. | -16.16x | 22.90x | 52.48x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- ZEAL Stock
- Valuation Zealand Pharma A/S
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition